| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.0039 | 0.9 |